nodes	percent_of_prediction	percent_of_DWPC	metapath
Famotidine—SLC47A1—Mitoxantrone—multiple sclerosis	0.481	0.598	CbGbCtD
Famotidine—SLC22A2—Cladribine—multiple sclerosis	0.204	0.254	CbGbCtD
Famotidine—SLC22A8—Methotrexate—multiple sclerosis	0.0532	0.0661	CbGbCtD
Famotidine—CYP2C19—Prednisone—multiple sclerosis	0.0408	0.0507	CbGbCtD
Famotidine—CYP2C19—Dexamethasone—multiple sclerosis	0.0255	0.0316	CbGbCtD
Famotidine—Hallucination—Prednisone—multiple sclerosis	0.000288	0.00149	CcSEcCtD
Famotidine—Pancytopenia—Methotrexate—multiple sclerosis	0.000287	0.00148	CcSEcCtD
Famotidine—Syncope—Triamcinolone—multiple sclerosis	0.000286	0.00148	CcSEcCtD
Famotidine—Syncope—Methylprednisolone—multiple sclerosis	0.000285	0.00147	CcSEcCtD
Famotidine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000284	0.00147	CcSEcCtD
Famotidine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000283	0.00146	CcSEcCtD
Famotidine—Oedema—Prednisolone—multiple sclerosis	0.000283	0.00146	CcSEcCtD
Famotidine—Neutropenia—Methotrexate—multiple sclerosis	0.000283	0.00146	CcSEcCtD
Famotidine—Dysuria—Methotrexate—multiple sclerosis	0.000283	0.00146	CcSEcCtD
Famotidine—Dizziness—Azathioprine—multiple sclerosis	0.000282	0.00146	CcSEcCtD
Famotidine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000282	0.00146	CcSEcCtD
Famotidine—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000281	0.00145	CcSEcCtD
Famotidine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.00028	0.00145	CcSEcCtD
Famotidine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.00028	0.00144	CcSEcCtD
Famotidine—Shock—Prednisolone—multiple sclerosis	0.000278	0.00144	CcSEcCtD
Famotidine—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000278	0.00144	CcSEcCtD
Famotidine—Cough—Triamcinolone—multiple sclerosis	0.000278	0.00144	CcSEcCtD
Famotidine—Convulsion—Triamcinolone—multiple sclerosis	0.000276	0.00143	CcSEcCtD
Famotidine—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000276	0.00143	CcSEcCtD
Famotidine—Convulsion—Methylprednisolone—multiple sclerosis	0.000276	0.00142	CcSEcCtD
Famotidine—Urticaria—Mitoxantrone—multiple sclerosis	0.000274	0.00142	CcSEcCtD
Famotidine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000273	0.00141	CcSEcCtD
Famotidine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000273	0.00141	CcSEcCtD
Famotidine—Myalgia—Triamcinolone—multiple sclerosis	0.000272	0.0014	CcSEcCtD
Famotidine—Vomiting—Azathioprine—multiple sclerosis	0.000271	0.0014	CcSEcCtD
Famotidine—Myalgia—Methylprednisolone—multiple sclerosis	0.000271	0.0014	CcSEcCtD
Famotidine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000271	0.0014	CcSEcCtD
Famotidine—Anxiety—Methylprednisolone—multiple sclerosis	0.00027	0.00139	CcSEcCtD
Famotidine—Rash—Azathioprine—multiple sclerosis	0.000269	0.00139	CcSEcCtD
Famotidine—Dermatitis—Azathioprine—multiple sclerosis	0.000269	0.00139	CcSEcCtD
Famotidine—Depression—Methotrexate—multiple sclerosis	0.000269	0.00139	CcSEcCtD
Famotidine—Flushing—Prednisone—multiple sclerosis	0.000269	0.00139	CcSEcCtD
Famotidine—Headache—Azathioprine—multiple sclerosis	0.000267	0.00138	CcSEcCtD
Famotidine—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000267	0.00138	CcSEcCtD
Famotidine—Dry mouth—Triamcinolone—multiple sclerosis	0.000266	0.00137	CcSEcCtD
Famotidine—Angioedema—Betamethasone—multiple sclerosis	0.000264	0.00137	CcSEcCtD
Famotidine—Angioedema—Dexamethasone—multiple sclerosis	0.000264	0.00137	CcSEcCtD
Famotidine—Confusional state—Methylprednisolone—multiple sclerosis	0.000262	0.00135	CcSEcCtD
Famotidine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.00026	0.00134	CcSEcCtD
Famotidine—Oedema—Triamcinolone—multiple sclerosis	0.00026	0.00134	CcSEcCtD
Famotidine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00026	0.00134	CcSEcCtD
Famotidine—Syncope—Dexamethasone—multiple sclerosis	0.00026	0.00134	CcSEcCtD
Famotidine—Syncope—Betamethasone—multiple sclerosis	0.00026	0.00134	CcSEcCtD
Famotidine—Arrhythmia—Prednisone—multiple sclerosis	0.000259	0.00134	CcSEcCtD
Famotidine—Infection—Triamcinolone—multiple sclerosis	0.000259	0.00134	CcSEcCtD
Famotidine—Infection—Methylprednisolone—multiple sclerosis	0.000258	0.00133	CcSEcCtD
Famotidine—Haematuria—Methotrexate—multiple sclerosis	0.000257	0.00133	CcSEcCtD
Famotidine—Shock—Triamcinolone—multiple sclerosis	0.000256	0.00132	CcSEcCtD
Famotidine—Insomnia—Prednisolone—multiple sclerosis	0.000256	0.00132	CcSEcCtD
Famotidine—Alopecia—Prednisone—multiple sclerosis	0.000256	0.00132	CcSEcCtD
Famotidine—Shock—Methylprednisolone—multiple sclerosis	0.000256	0.00132	CcSEcCtD
Famotidine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Paraesthesia—Prednisolone—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Mental disorder—Prednisone—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Nausea—Azathioprine—multiple sclerosis	0.000254	0.00131	CcSEcCtD
Famotidine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000252	0.0013	CcSEcCtD
Famotidine—Convulsion—Dexamethasone—multiple sclerosis	0.000251	0.0013	CcSEcCtD
Famotidine—Convulsion—Betamethasone—multiple sclerosis	0.000251	0.0013	CcSEcCtD
Famotidine—Asthenia—Mitoxantrone—multiple sclerosis	0.000248	0.00128	CcSEcCtD
Famotidine—Myalgia—Dexamethasone—multiple sclerosis	0.000246	0.00127	CcSEcCtD
Famotidine—Myalgia—Betamethasone—multiple sclerosis	0.000246	0.00127	CcSEcCtD
Famotidine—Anxiety—Dexamethasone—multiple sclerosis	0.000246	0.00127	CcSEcCtD
Famotidine—Anxiety—Betamethasone—multiple sclerosis	0.000246	0.00127	CcSEcCtD
Famotidine—Pain—Prednisolone—multiple sclerosis	0.000242	0.00125	CcSEcCtD
Famotidine—Hepatitis—Methotrexate—multiple sclerosis	0.000242	0.00125	CcSEcCtD
Famotidine—Pharyngitis—Methotrexate—multiple sclerosis	0.00024	0.00124	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000237	0.00123	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000237	0.00122	CcSEcCtD
Famotidine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000236	0.00122	CcSEcCtD
Famotidine—Oedema—Betamethasone—multiple sclerosis	0.000236	0.00122	CcSEcCtD
Famotidine—Oedema—Dexamethasone—multiple sclerosis	0.000236	0.00122	CcSEcCtD
Famotidine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000236	0.00122	CcSEcCtD
Famotidine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000236	0.00122	CcSEcCtD
Famotidine—Insomnia—Triamcinolone—multiple sclerosis	0.000235	0.00122	CcSEcCtD
Famotidine—Insomnia—Methylprednisolone—multiple sclerosis	0.000235	0.00121	CcSEcCtD
Famotidine—Infection—Betamethasone—multiple sclerosis	0.000235	0.00121	CcSEcCtD
Famotidine—Infection—Dexamethasone—multiple sclerosis	0.000235	0.00121	CcSEcCtD
Famotidine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000234	0.00121	CcSEcCtD
Famotidine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000233	0.00121	CcSEcCtD
Famotidine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000233	0.0012	CcSEcCtD
Famotidine—Anaemia—Prednisone—multiple sclerosis	0.000233	0.0012	CcSEcCtD
Famotidine—Shock—Betamethasone—multiple sclerosis	0.000232	0.0012	CcSEcCtD
Famotidine—Shock—Dexamethasone—multiple sclerosis	0.000232	0.0012	CcSEcCtD
Famotidine—Agitation—Prednisone—multiple sclerosis	0.000232	0.0012	CcSEcCtD
Famotidine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000231	0.00119	CcSEcCtD
Famotidine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000231	0.00119	CcSEcCtD
Famotidine—Angioedema—Prednisone—multiple sclerosis	0.00023	0.00119	CcSEcCtD
Famotidine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000229	0.00118	CcSEcCtD
Famotidine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000229	0.00118	CcSEcCtD
Famotidine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000229	0.00118	CcSEcCtD
Famotidine—Syncope—Prednisone—multiple sclerosis	0.000226	0.00117	CcSEcCtD
Famotidine—Tinnitus—Methotrexate—multiple sclerosis	0.000226	0.00117	CcSEcCtD
Famotidine—Anorexia—Betamethasone—multiple sclerosis	0.000225	0.00116	CcSEcCtD
Famotidine—Anorexia—Dexamethasone—multiple sclerosis	0.000225	0.00116	CcSEcCtD
Famotidine—Urticaria—Prednisolone—multiple sclerosis	0.000225	0.00116	CcSEcCtD
Famotidine—Fatigue—Triamcinolone—multiple sclerosis	0.000224	0.00116	CcSEcCtD
Famotidine—Fatigue—Methylprednisolone—multiple sclerosis	0.000224	0.00116	CcSEcCtD
Famotidine—Pain—Triamcinolone—multiple sclerosis	0.000223	0.00115	CcSEcCtD
Famotidine—Loss of consciousness—Prednisone—multiple sclerosis	0.000222	0.00114	CcSEcCtD
Famotidine—Vomiting—Mitoxantrone—multiple sclerosis	0.000219	0.00113	CcSEcCtD
Famotidine—Convulsion—Prednisone—multiple sclerosis	0.000218	0.00113	CcSEcCtD
Famotidine—Rash—Mitoxantrone—multiple sclerosis	0.000218	0.00112	CcSEcCtD
Famotidine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000217	0.00112	CcSEcCtD
Famotidine—Headache—Mitoxantrone—multiple sclerosis	0.000216	0.00112	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000215	0.00111	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000215	0.00111	CcSEcCtD
Famotidine—Arthralgia—Prednisone—multiple sclerosis	0.000215	0.00111	CcSEcCtD
Famotidine—Myalgia—Prednisone—multiple sclerosis	0.000215	0.00111	CcSEcCtD
Famotidine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000215	0.00111	CcSEcCtD
Famotidine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000214	0.00111	CcSEcCtD
Famotidine—Anxiety—Prednisone—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Famotidine—Alopecia—Methotrexate—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Famotidine—Insomnia—Dexamethasone—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Famotidine—Insomnia—Betamethasone—multiple sclerosis	0.000214	0.0011	CcSEcCtD
Famotidine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000212	0.0011	CcSEcCtD
Famotidine—Paraesthesia—Betamethasone—multiple sclerosis	0.000212	0.0011	CcSEcCtD
Famotidine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000212	0.0011	CcSEcCtD
Famotidine—Mental disorder—Methotrexate—multiple sclerosis	0.000212	0.0011	CcSEcCtD
Famotidine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000209	0.00108	CcSEcCtD
Famotidine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000208	0.00107	CcSEcCtD
Famotidine—Dyspepsia—Betamethasone—multiple sclerosis	0.000208	0.00107	CcSEcCtD
Famotidine—Urticaria—Triamcinolone—multiple sclerosis	0.000207	0.00107	CcSEcCtD
Famotidine—Urticaria—Methylprednisolone—multiple sclerosis	0.000206	0.00107	CcSEcCtD
Famotidine—Dysgeusia—Methotrexate—multiple sclerosis	0.000206	0.00107	CcSEcCtD
Famotidine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000206	0.00106	CcSEcCtD
Famotidine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000206	0.00106	CcSEcCtD
Famotidine—Oedema—Prednisone—multiple sclerosis	0.000206	0.00106	CcSEcCtD
Famotidine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000205	0.00106	CcSEcCtD
Famotidine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000205	0.00106	CcSEcCtD
Famotidine—Decreased appetite—Betamethasone—multiple sclerosis	0.000205	0.00106	CcSEcCtD
Famotidine—Nausea—Mitoxantrone—multiple sclerosis	0.000205	0.00106	CcSEcCtD
Famotidine—Infection—Prednisone—multiple sclerosis	0.000204	0.00106	CcSEcCtD
Famotidine—Back pain—Methotrexate—multiple sclerosis	0.000204	0.00105	CcSEcCtD
Famotidine—Fatigue—Betamethasone—multiple sclerosis	0.000204	0.00105	CcSEcCtD
Famotidine—Fatigue—Dexamethasone—multiple sclerosis	0.000204	0.00105	CcSEcCtD
Famotidine—Shock—Prednisone—multiple sclerosis	0.000202	0.00105	CcSEcCtD
Famotidine—Pain—Betamethasone—multiple sclerosis	0.000202	0.00104	CcSEcCtD
Famotidine—Pain—Dexamethasone—multiple sclerosis	0.000202	0.00104	CcSEcCtD
Famotidine—Anorexia—Prednisone—multiple sclerosis	0.000196	0.00101	CcSEcCtD
Famotidine—Anaemia—Methotrexate—multiple sclerosis	0.000195	0.00101	CcSEcCtD
Famotidine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000195	0.00101	CcSEcCtD
Famotidine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000195	0.00101	CcSEcCtD
Famotidine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000193	0.000998	CcSEcCtD
Famotidine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000193	0.000998	CcSEcCtD
Famotidine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000192	0.000991	CcSEcCtD
Famotidine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000191	0.000989	CcSEcCtD
Famotidine—Leukopenia—Methotrexate—multiple sclerosis	0.000189	0.000974	CcSEcCtD
Famotidine—Urticaria—Betamethasone—multiple sclerosis	0.000188	0.000969	CcSEcCtD
Famotidine—Urticaria—Dexamethasone—multiple sclerosis	0.000188	0.000969	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000187	0.000968	CcSEcCtD
Famotidine—Dizziness—Prednisolone—multiple sclerosis	0.000187	0.000967	CcSEcCtD
Famotidine—Asthenia—Triamcinolone—multiple sclerosis	0.000187	0.000965	CcSEcCtD
Famotidine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000187	0.000965	CcSEcCtD
Famotidine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000187	0.000965	CcSEcCtD
Famotidine—Body temperature increased—Betamethasone—multiple sclerosis	0.000187	0.000965	CcSEcCtD
Famotidine—Abdominal pain—Betamethasone—multiple sclerosis	0.000187	0.000965	CcSEcCtD
Famotidine—Asthenia—Methylprednisolone—multiple sclerosis	0.000186	0.000963	CcSEcCtD
Famotidine—Insomnia—Prednisone—multiple sclerosis	0.000186	0.000961	CcSEcCtD
Famotidine—Paraesthesia—Prednisone—multiple sclerosis	0.000185	0.000954	CcSEcCtD
Famotidine—Pruritus—Triamcinolone—multiple sclerosis	0.000184	0.000951	CcSEcCtD
Famotidine—Cough—Methotrexate—multiple sclerosis	0.000184	0.00095	CcSEcCtD
Famotidine—Pruritus—Methylprednisolone—multiple sclerosis	0.000184	0.000949	CcSEcCtD
Famotidine—Convulsion—Methotrexate—multiple sclerosis	0.000183	0.000943	CcSEcCtD
Famotidine—Dyspepsia—Prednisone—multiple sclerosis	0.000181	0.000935	CcSEcCtD
Famotidine—Myalgia—Methotrexate—multiple sclerosis	0.000179	0.000926	CcSEcCtD
Famotidine—Arthralgia—Methotrexate—multiple sclerosis	0.000179	0.000926	CcSEcCtD
Famotidine—Chest pain—Methotrexate—multiple sclerosis	0.000179	0.000926	CcSEcCtD
Famotidine—Decreased appetite—Prednisone—multiple sclerosis	0.000179	0.000924	CcSEcCtD
Famotidine—Rash—Prednisolone—multiple sclerosis	0.000178	0.000922	CcSEcCtD
Famotidine—Dermatitis—Prednisolone—multiple sclerosis	0.000178	0.000921	CcSEcCtD
Famotidine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000178	0.000918	CcSEcCtD
Famotidine—Fatigue—Prednisone—multiple sclerosis	0.000177	0.000916	CcSEcCtD
Famotidine—Headache—Prednisolone—multiple sclerosis	0.000177	0.000916	CcSEcCtD
Famotidine—Constipation—Prednisone—multiple sclerosis	0.000176	0.000909	CcSEcCtD
Famotidine—Confusional state—Methotrexate—multiple sclerosis	0.000173	0.000895	CcSEcCtD
Famotidine—Dizziness—Triamcinolone—multiple sclerosis	0.000172	0.000889	CcSEcCtD
Famotidine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000172	0.000888	CcSEcCtD
Famotidine—Dizziness—Methylprednisolone—multiple sclerosis	0.000172	0.000887	CcSEcCtD
Famotidine—Infection—Methotrexate—multiple sclerosis	0.000171	0.000882	CcSEcCtD
Famotidine—Feeling abnormal—Prednisone—multiple sclerosis	0.00017	0.000876	CcSEcCtD
Famotidine—Asthenia—Betamethasone—multiple sclerosis	0.000169	0.000875	CcSEcCtD
Famotidine—Asthenia—Dexamethasone—multiple sclerosis	0.000169	0.000875	CcSEcCtD
Famotidine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000168	0.000869	CcSEcCtD
Famotidine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000168	0.000869	CcSEcCtD
Famotidine—Nausea—Prednisolone—multiple sclerosis	0.000168	0.000869	CcSEcCtD
Famotidine—Pruritus—Dexamethasone—multiple sclerosis	0.000167	0.000863	CcSEcCtD
Famotidine—Pruritus—Betamethasone—multiple sclerosis	0.000167	0.000863	CcSEcCtD
Famotidine—Vomiting—Triamcinolone—multiple sclerosis	0.000166	0.000855	CcSEcCtD
Famotidine—Vomiting—Methylprednisolone—multiple sclerosis	0.000165	0.000853	CcSEcCtD
Famotidine—Rash—Triamcinolone—multiple sclerosis	0.000164	0.000848	CcSEcCtD
Famotidine—Dermatitis—Triamcinolone—multiple sclerosis	0.000164	0.000847	CcSEcCtD
Famotidine—Anorexia—Methotrexate—multiple sclerosis	0.000164	0.000846	CcSEcCtD
Famotidine—Rash—Methylprednisolone—multiple sclerosis	0.000164	0.000846	CcSEcCtD
Famotidine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000164	0.000845	CcSEcCtD
Famotidine—Urticaria—Prednisone—multiple sclerosis	0.000163	0.000844	CcSEcCtD
Famotidine—Headache—Triamcinolone—multiple sclerosis	0.000163	0.000842	CcSEcCtD
Famotidine—Headache—Methylprednisolone—multiple sclerosis	0.000163	0.000841	CcSEcCtD
Famotidine—Abdominal pain—Prednisone—multiple sclerosis	0.000163	0.00084	CcSEcCtD
Famotidine—Body temperature increased—Prednisone—multiple sclerosis	0.000163	0.00084	CcSEcCtD
Famotidine—Diarrhoea—Betamethasone—multiple sclerosis	0.000162	0.000835	CcSEcCtD
Famotidine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000162	0.000835	CcSEcCtD
Famotidine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000157	0.000809	CcSEcCtD
Famotidine—Dizziness—Dexamethasone—multiple sclerosis	0.000156	0.000807	CcSEcCtD
Famotidine—Dizziness—Betamethasone—multiple sclerosis	0.000156	0.000807	CcSEcCtD
Famotidine—Insomnia—Methotrexate—multiple sclerosis	0.000155	0.000803	CcSEcCtD
Famotidine—Nausea—Triamcinolone—multiple sclerosis	0.000155	0.000799	CcSEcCtD
Famotidine—Paraesthesia—Methotrexate—multiple sclerosis	0.000154	0.000797	CcSEcCtD
Famotidine—Nausea—Methylprednisolone—multiple sclerosis	0.000154	0.000797	CcSEcCtD
Famotidine—Somnolence—Methotrexate—multiple sclerosis	0.000153	0.000789	CcSEcCtD
Famotidine—Hypersensitivity—Prednisone—multiple sclerosis	0.000152	0.000783	CcSEcCtD
Famotidine—Dyspepsia—Methotrexate—multiple sclerosis	0.000151	0.000782	CcSEcCtD
Famotidine—Vomiting—Betamethasone—multiple sclerosis	0.00015	0.000776	CcSEcCtD
Famotidine—Vomiting—Dexamethasone—multiple sclerosis	0.00015	0.000776	CcSEcCtD
Famotidine—Decreased appetite—Methotrexate—multiple sclerosis	0.000149	0.000772	CcSEcCtD
Famotidine—Rash—Betamethasone—multiple sclerosis	0.000149	0.000769	CcSEcCtD
Famotidine—Rash—Dexamethasone—multiple sclerosis	0.000149	0.000769	CcSEcCtD
Famotidine—Dermatitis—Dexamethasone—multiple sclerosis	0.000149	0.000769	CcSEcCtD
Famotidine—Dermatitis—Betamethasone—multiple sclerosis	0.000149	0.000769	CcSEcCtD
Famotidine—Fatigue—Methotrexate—multiple sclerosis	0.000148	0.000766	CcSEcCtD
Famotidine—Headache—Betamethasone—multiple sclerosis	0.000148	0.000764	CcSEcCtD
Famotidine—Headache—Dexamethasone—multiple sclerosis	0.000148	0.000764	CcSEcCtD
Famotidine—Asthenia—Prednisone—multiple sclerosis	0.000148	0.000762	CcSEcCtD
Famotidine—Pain—Methotrexate—multiple sclerosis	0.000147	0.000759	CcSEcCtD
Famotidine—Pruritus—Prednisone—multiple sclerosis	0.000146	0.000752	CcSEcCtD
Famotidine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000142	0.000732	CcSEcCtD
Famotidine—Diarrhoea—Prednisone—multiple sclerosis	0.000141	0.000727	CcSEcCtD
Famotidine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000141	0.000726	CcSEcCtD
Famotidine—Nausea—Betamethasone—multiple sclerosis	0.00014	0.000725	CcSEcCtD
Famotidine—Nausea—Dexamethasone—multiple sclerosis	0.00014	0.000725	CcSEcCtD
Famotidine—Urticaria—Methotrexate—multiple sclerosis	0.000137	0.000705	CcSEcCtD
Famotidine—SLC22A2—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—multiple sclerosis	0.000136	0.064	CbGpPWpGaD
Famotidine—Dizziness—Prednisone—multiple sclerosis	0.000136	0.000703	CcSEcCtD
Famotidine—Abdominal pain—Methotrexate—multiple sclerosis	0.000136	0.000702	CcSEcCtD
Famotidine—Body temperature increased—Methotrexate—multiple sclerosis	0.000136	0.000702	CcSEcCtD
Famotidine—Vomiting—Prednisone—multiple sclerosis	0.000131	0.000676	CcSEcCtD
Famotidine—Rash—Prednisone—multiple sclerosis	0.00013	0.00067	CcSEcCtD
Famotidine—Dermatitis—Prednisone—multiple sclerosis	0.00013	0.000669	CcSEcCtD
Famotidine—Headache—Prednisone—multiple sclerosis	0.000129	0.000666	CcSEcCtD
Famotidine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000127	0.000654	CcSEcCtD
Famotidine—Asthenia—Methotrexate—multiple sclerosis	0.000123	0.000637	CcSEcCtD
Famotidine—Nausea—Prednisone—multiple sclerosis	0.000122	0.000631	CcSEcCtD
Famotidine—Pruritus—Methotrexate—multiple sclerosis	0.000122	0.000628	CcSEcCtD
Famotidine—Diarrhoea—Methotrexate—multiple sclerosis	0.000118	0.000608	CcSEcCtD
Famotidine—Dizziness—Methotrexate—multiple sclerosis	0.000114	0.000587	CcSEcCtD
Famotidine—Vomiting—Methotrexate—multiple sclerosis	0.000109	0.000565	CcSEcCtD
Famotidine—Rash—Methotrexate—multiple sclerosis	0.000108	0.00056	CcSEcCtD
Famotidine—Dermatitis—Methotrexate—multiple sclerosis	0.000108	0.000559	CcSEcCtD
Famotidine—Headache—Methotrexate—multiple sclerosis	0.000108	0.000556	CcSEcCtD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000106	0.0496	CbGpPWpGaD
Famotidine—Nausea—Methotrexate—multiple sclerosis	0.000102	0.000527	CcSEcCtD
Famotidine—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	7.39e-05	0.0347	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	6.34e-05	0.0298	CbGpPWpGaD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	4.99e-05	0.0234	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	4.81e-05	0.0226	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	3.5e-05	0.0164	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	3.5e-05	0.0164	CbGpPWpGaD
Famotidine—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	3.48e-05	0.0163	CbGpPWpGaD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	3.47e-05	0.0163	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	3.45e-05	0.0162	CbGpPWpGaD
Famotidine—CYP2C19—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	3.45e-05	0.0162	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	3.36e-05	0.0158	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	3.22e-05	0.0151	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	2.99e-05	0.014	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—PTGER4—multiple sclerosis	2.94e-05	0.0138	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—KCNA3—multiple sclerosis	2.84e-05	0.0133	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	2.84e-05	0.0133	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	2.84e-05	0.0133	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—S1PR1—multiple sclerosis	2.77e-05	0.013	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—GPR65—multiple sclerosis	2.61e-05	0.0122	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	2.44e-05	0.0115	CbGpPWpGaD
Famotidine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	2.42e-05	0.0114	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CCR1—multiple sclerosis	2.39e-05	0.0112	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	2.27e-05	0.0106	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—GPR65—multiple sclerosis	2.24e-05	0.0105	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—S1PR1—multiple sclerosis	2.11e-05	0.00991	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	2.08e-05	0.00976	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	2.05e-05	0.0096	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	2.05e-05	0.0096	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	1.93e-05	0.00906	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.71e-05	0.00801	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—GPR65—multiple sclerosis	1.7e-05	0.00799	CbGpPWpGaD
Famotidine—CYP2C19—Melatonin metabolism and effects—APOE—multiple sclerosis	1.64e-05	0.00769	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	1.64e-05	0.00768	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	1.58e-05	0.00743	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	1.58e-05	0.00742	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	1.58e-05	0.0074	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CXCL13—multiple sclerosis	1.56e-05	0.00731	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCR1—multiple sclerosis	1.56e-05	0.00731	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	1.54e-05	0.00722	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.52e-05	0.00713	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP24A1—multiple sclerosis	1.51e-05	0.00707	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—CYP27B1—multiple sclerosis	1.51e-05	0.00707	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP24A1—multiple sclerosis	1.49e-05	0.00697	CbGpPWpGaD
Famotidine—CYP2C19—Metapathway biotransformation—CYP27B1—multiple sclerosis	1.49e-05	0.00697	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	1.46e-05	0.00684	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	1.42e-05	0.00666	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	1.4e-05	0.00658	CbGpPWpGaD
Famotidine—HRH2—G alpha (s) signalling events—POMC—multiple sclerosis	1.39e-05	0.00653	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	1.36e-05	0.00636	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	1.32e-05	0.00618	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	1.22e-05	0.00571	CbGpPWpGaD
Famotidine—SLC47A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	1.21e-05	0.00567	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—S1PR1—multiple sclerosis	1.19e-05	0.0056	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	1.15e-05	0.0054	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCL3—multiple sclerosis	1.11e-05	0.00521	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	1.1e-05	0.00517	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	1.1e-05	0.00514	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—S1PR1—multiple sclerosis	1.08e-05	0.00509	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—PTGER4—multiple sclerosis	1.07e-05	0.00501	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	1.06e-05	0.00496	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—BCHE—multiple sclerosis	1.04e-05	0.00487	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CXCR3—multiple sclerosis	1.03e-05	0.00484	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—RGS1—multiple sclerosis	1.02e-05	0.00476	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCR2—multiple sclerosis	1e-05	0.00471	CbGpPWpGaD
Famotidine—HRH2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	9.91e-06	0.00465	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—GPR65—multiple sclerosis	9.62e-06	0.00452	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	9.43e-06	0.00442	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CNR1—multiple sclerosis	9.26e-06	0.00435	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—RGS1—multiple sclerosis	9.22e-06	0.00433	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—AQP4—multiple sclerosis	9.1e-06	0.00427	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CCR1—multiple sclerosis	8.8e-06	0.00413	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCL13—multiple sclerosis	8.8e-06	0.00413	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—GPR65—multiple sclerosis	8.74e-06	0.0041	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	8.49e-06	0.00399	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—LINGO1—multiple sclerosis	8.45e-06	0.00397	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CXCL10—multiple sclerosis	8.34e-06	0.00391	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	8.04e-06	0.00377	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	8.01e-06	0.00376	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCL13—multiple sclerosis	7.99e-06	0.00375	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCR1—multiple sclerosis	7.99e-06	0.00375	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—BCHE—multiple sclerosis	7.95e-06	0.00373	CbGpPWpGaD
Famotidine—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.87e-06	0.00369	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TAGAP—multiple sclerosis	7.33e-06	0.00344	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCL5—multiple sclerosis	7.18e-06	0.00337	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	6.64e-06	0.00311	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—SRM—multiple sclerosis	6.53e-06	0.00306	CbGpPWpGaD
Famotidine—HRH2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	6.5e-06	0.00305	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCR5—multiple sclerosis	6.47e-06	0.00303	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—S1PR1—multiple sclerosis	6.41e-06	0.00301	CbGpPWpGaD
Famotidine—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.38e-06	0.00299	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	6.33e-06	0.00297	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GPC5—multiple sclerosis	6.23e-06	0.00292	CbGpPWpGaD
Famotidine—SLC47A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	6.15e-06	0.00288	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—PTGER4—multiple sclerosis	6.04e-06	0.00283	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCR3—multiple sclerosis	5.83e-06	0.00274	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.78e-06	0.00271	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.78e-06	0.00271	CbGpPWpGaD
Famotidine—SLC22A8—SLC-mediated transmembrane transport—ALB—multiple sclerosis	5.7e-06	0.00267	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCL3—multiple sclerosis	5.7e-06	0.00267	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CCR2—multiple sclerosis	5.67e-06	0.00266	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.6e-06	0.00263	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—PTGER4—multiple sclerosis	5.48e-06	0.00257	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—RGS1—multiple sclerosis	5.45e-06	0.00256	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCR3—multiple sclerosis	5.3e-06	0.00248	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CNR1—multiple sclerosis	5.23e-06	0.00246	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—GPR65—multiple sclerosis	5.16e-06	0.00242	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCR2—multiple sclerosis	5.15e-06	0.00242	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—POMC—multiple sclerosis	5.06e-06	0.00237	CbGpPWpGaD
Famotidine—HRH2—GPCR ligand binding—CCL2—multiple sclerosis	4.95e-06	0.00232	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CNR1—multiple sclerosis	4.75e-06	0.00223	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCR1—multiple sclerosis	4.72e-06	0.00222	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL13—multiple sclerosis	4.72e-06	0.00222	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CXCL10—multiple sclerosis	4.71e-06	0.00221	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP27B1—multiple sclerosis	4.6e-06	0.00216	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—CYP24A1—multiple sclerosis	4.6e-06	0.00216	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CXCL10—multiple sclerosis	4.28e-06	0.00201	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—GPC5—multiple sclerosis	4.21e-06	0.00197	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CCL5—multiple sclerosis	4.06e-06	0.0019	CbGpPWpGaD
Famotidine—SLC22A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.97e-06	0.00186	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCL5—multiple sclerosis	3.68e-06	0.00173	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—SRM—multiple sclerosis	3.66e-06	0.00172	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—CCR5—multiple sclerosis	3.66e-06	0.00172	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IL2RA—multiple sclerosis	3.6e-06	0.00169	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—RRM1—multiple sclerosis	3.49e-06	0.00164	CbGpPWpGaD
Famotidine—CYP2C19—Biological oxidations—POMC—multiple sclerosis	3.39e-06	0.00159	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCL3—multiple sclerosis	3.36e-06	0.00158	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCR5—multiple sclerosis	3.32e-06	0.00156	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL2RA—multiple sclerosis	3.27e-06	0.00153	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PTGER4—multiple sclerosis	3.24e-06	0.00152	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—PGR—multiple sclerosis	3.19e-06	0.0015	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCR3—multiple sclerosis	3.13e-06	0.00147	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CD28—multiple sclerosis	3.1e-06	0.00145	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCR2—multiple sclerosis	3.04e-06	0.00143	CbGpPWpGaD
Famotidine—SLC22A2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.03e-06	0.00142	CbGpPWpGaD
Famotidine—SLC22A8—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.9e-06	0.00136	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—POMC—multiple sclerosis	2.86e-06	0.00134	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CNR1—multiple sclerosis	2.81e-06	0.00132	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—POMC—multiple sclerosis	2.59e-06	0.00122	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.58e-06	0.00121	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.58e-06	0.00121	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—CCL2—multiple sclerosis	2.54e-06	0.00119	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CXCL10—multiple sclerosis	2.53e-06	0.00119	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.52e-06	0.00118	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—GPC5—multiple sclerosis	2.36e-06	0.00111	CbGpPWpGaD
Famotidine—SLC22A2—Neuronal System—MAPK1—multiple sclerosis	2.32e-06	0.00109	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—TYK2—multiple sclerosis	2.3e-06	0.00108	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CD86—multiple sclerosis	2.21e-06	0.00104	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCL5—multiple sclerosis	2.18e-06	0.00102	CbGpPWpGaD
Famotidine—HRH2—GPCR downstream signaling—IL2—multiple sclerosis	2.11e-06	0.000991	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—SPP1—multiple sclerosis	2.02e-06	0.000946	CbGpPWpGaD
Famotidine—SLC22A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.02e-06	0.000945	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—BCHE—multiple sclerosis	2e-06	0.00094	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCR5—multiple sclerosis	1.96e-06	0.00092	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.95e-06	0.000916	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL2RA—multiple sclerosis	1.93e-06	0.000907	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL2—multiple sclerosis	1.92e-06	0.0009	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—APOE—multiple sclerosis	1.78e-06	0.000837	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CD80—multiple sclerosis	1.61e-06	0.000757	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—POMC—multiple sclerosis	1.53e-06	0.000719	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.51e-06	0.000711	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—CCL2—multiple sclerosis	1.5e-06	0.000704	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—MAPK1—multiple sclerosis	1.47e-06	0.000688	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TYK2—multiple sclerosis	1.36e-06	0.000639	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.3e-06	0.00061	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—APOE—multiple sclerosis	1.21e-06	0.000565	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.19e-06	0.000557	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL2—multiple sclerosis	1.13e-06	0.000532	CbGpPWpGaD
Famotidine—HRH2—Signaling by GPCR—IL6—multiple sclerosis	1.13e-06	0.000529	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.12e-06	0.000526	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MMP9—multiple sclerosis	1.07e-06	0.000503	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—POMC—multiple sclerosis	1.04e-06	0.000486	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—STAT3—multiple sclerosis	9.53e-07	0.000447	CbGpPWpGaD
Famotidine—SLC22A2—Metabolism—ALB—multiple sclerosis	9.44e-07	0.000443	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MYC—multiple sclerosis	8.86e-07	0.000416	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—TGFB1—multiple sclerosis	8.84e-07	0.000415	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—MAPK1—multiple sclerosis	8.67e-07	0.000407	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—APOE—multiple sclerosis	6.74e-07	0.000316	CbGpPWpGaD
Famotidine—HRH2—Signaling Pathways—IL6—multiple sclerosis	6.66e-07	0.000312	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—POMC—multiple sclerosis	5.79e-07	0.000272	CbGpPWpGaD
Famotidine—CYP2C19—Metabolism—ALB—multiple sclerosis	5.28e-07	0.000248	CbGpPWpGaD
